Vape PMTA (section 910) vs Substantial Equivalence (section 905(j))
PMTA vs Substantial Equivalence: which FDA tobacco pathway do you need?
A PMTA (section 910) proves a new tobacco product is appropriate for the protection of public health from its own evidence — the default route for novel products like most ENDS. A Substantial Equivalence report (section 905(j)) instead shows the product is equivalent to a predicate marketed as of 15 February 2007. SE is lighter but needs a valid predicate; without one, PMTA is the only route.
| PMTA (section 910) | Substantial Equivalence (section 905(j)) | |
|---|---|---|
| Statutory basis | Section 910 of the FD&C Act; procedures in 21 CFR Part 1114 | Section 905(j) of the FD&C Act; content and format in 21 CFR Part 1107 |
| Authorisation standard | Product is appropriate for the protection of public health (APPH), judged on the population as a whole | Product has the same characteristics as a predicate, or different characteristics that do not raise different questions of public health |
| Predicate required | No predicate — the application stands on its own evidence | Yes — a product commercially marketed in the US as of 15 February 2007, or one FDA previously found substantially equivalent |
| Evidence burden | Comprehensive — health-risk investigations, toxicology, abuse-liability and behavioural data, manufacturing, design, and an environmental assessment | Comparative — a side-by-side showing no new or increased questions of public health relative to the predicate, plus an environmental assessment |
| Typical use | Novel products with no valid predicate — most ENDS, e-liquids, modern vaping systems | A modification of an existing product, or a product closely matching a pre-2007 predicate |
| Acceptance / filing gates | Acceptance + filing review under 21 CFR 1114.27 before substantive review | Acceptance review under 21 CFR 1107; missing required content draws a refuse-to-accept decision |
| Successful outcome | A marketing granted order authorising sale | An order finding the product substantially equivalent |
| Environmental assessment | Required — no categorical exclusion exists for tobacco products | Required — same NEPA obligation applies |
The short answer
The pathway is not a preference — it is dictated by whether you have a valid predicate. A Substantial Equivalence report under section 905(j) is the lighter route, but it only exists if your product is equivalent to a tobacco product that was commercially marketed in the United States as of 15 February 2007, or one FDA has already found substantially equivalent. If no such predicate exists — which is the case for almost every modern ENDS and e-liquid — the PMTA under section 910 is your only route, and it carries the full evidentiary burden of proving the product is appropriate for the protection of public health.
How to choose
Start from the predicate question, because it closes off one route entirely.
If your product closely matches a pre-2007 predicate, or a minor modification of a product FDA already cleared, the SE pathway compares the two and asks whether the differences raise different questions of public health. The work is comparative: a structured side-by-side of design, materials, and emissions, backed by data showing the new product is not more harmful than the predicate. The burden is real but bounded by the predicate.
If there is no valid predicate, the SE route is closed. The PMTA stands on its own evidence — health-risk investigations, toxicology, abuse-liability and behavioural studies, manufacturing detail, and full design parameters — and FDA judges the product against the protection of the population as a whole, including the pull on non-users and youth. This is why most vaping products go the PMTA route: the category did not exist in a comparable form in 2007, so there is nothing to be equivalent to.
What both routes share
Both pathways run administrative gates before any scientific review, and both can be turned away at the door for missing content rather than weak science. Both require an environmental assessment — there is no categorical exclusion for tobacco products, so its absence or inadequacy is a leading cause of early rejection on either route. The completeness discipline is identical; what differs is the standard the evidence has to meet. For the operational detail on those gates, see what gets a PMTA refused at FDA’s acceptance and filing review.
Verdict
Choose SE only if you can name a valid predicate and defend equivalence; the route is lighter but the predicate is the gate. Default to PMTA for anything novel — it is more work, but for most ENDS it is the only authorisation that exists. Either way, the evidence-assembly burden (and the administrative completeness that decides whether FDA even reviews you) is where the timeline is won or lost.
Sources
Last reviewed . Pathways and rules change — confirm against the cited primary source.